Clinical trials: sponsored by Glaukos Corporation
- Lead sponsor (exact) Glaukos Corporation
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Keratoconus
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.
- Trial name
- NCT07629557
- Testing
- Riboflavin Ophthalmic Solutions, UV-A Irradiation System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Glaukos Corporation
Persistent Corneal Epithelial Defect
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED).
- Trial name
- NEXPEDE-1 (NCT05966493)
- Testing
- lufepirsen high dose, Vehicle, lufepirsen low dose
- Where
- 28 sites in United States, Germany and 2 more
- Volunteers
- 84 people
- Sponsor
- Glaukos Corporation
Corneal Persistent Epithelial Defect
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care…
- Trial name
- EXPEDE (NCT04081103)
- Testing
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Glaukos Corporation
Progressive Keratoconus
Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus.
- Trial name
- NCT03442751
- Testing
- Test Article A, Test Article B, KXL medical device system
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle
iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study
Long term follow up of subjects in the IDE study for iStent Inject to monitor safety
- Trial name
- NCT04624685
- Where
- 24 sites in United States
- Volunteers
- 475 people
- Sponsor
- Glaukos Corporation
Keratoconus
Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus
The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression…
- Trial name
- NCT01972854
- Testing
- riboflavin solution, KXL System
- Where
- 11 sites in United States
- Volunteers
- 92 people
- Sponsor
- Glaukos Corporation
Keratoconus
Feasibility Study of the Vedera KXS for Treatment of Keratoconus
The objective of this investigation is to evaluate the feasibility, safety and efficacy of the Vedera KXS for the reduction or elimination of myopia and astigmatism in patients with keratoconus, who are no longer able to achieve…
- Trial name
- NCT01069848
- Testing
- Vedera KXS
- Where
- Turkey (Türkiye)
- Volunteers
- 23 people
- Sponsor
- Glaukos Corporation
Keratoconus
Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression…
- Trial name
- NCT01344187
- Testing
- riboflavin solution, KXL System
- Where
- 10 sites in United States
- Volunteers
- 236 people
- Sponsor
- Glaukos Corporation
Keratoconus
Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression…
- Trial name
- NCT01643226
- Testing
- riboflavin solution, KXL System
- Where
- 8 sites in United States
- Volunteers
- 230 people
- Sponsor
- Glaukos Corporation
Corneal Ectasia
Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery
The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression…
- Trial name
- NCT01643252
- Testing
- riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system
- Sponsor
- Glaukos Corporation
Ectasia
Corneal Collagen Cross-Linking for Ectasia (CXL)
Prospective, randomized multicenter study to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes with ectasia after refractive surgery.
- Trial name
- CXL (NCT00674661)
- Testing
- riboflavin ophthalmic solution, UVA Irradiation
- Where
- 10 sites in United States
- Volunteers
- 130 people
- Sponsor
- Glaukos Corporation
Progressive Keratoconus
Corneal Collagen Cross-linking for Progressive Keratoconus
Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.
- Trial name
- CXL (NCT00647699)
- Testing
- riboflavin ophthalmic solution, UVA Irradiation
- Where
- 10 sites in United States
- Volunteers
- 147 people
- Sponsor
- Glaukos Corporation
Primary Open-angle Glaucoma
Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry
The purpose of this study is to observe the safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery in subjects with mild to moderate open-angle glaucoma.
- Trial name
- NCT01841437
- Testing
- iStent
- Where
- 18 sites in United States
- Volunteers
- 191 people
- Sponsor
- Glaukos Corporation
Primary Open Angle Glaucoma
Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort
The purpose of this study is to assess the long-term safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100R/L in subjects previously enrolled in Glaukos Study GC-003.
- Trial name
- NCT01836042
- Where
- 26 sites in United States
- Volunteers
- 108 people
- Sponsor
- Glaukos Corporation